SEC 13F Intelligence

Managers / Q1 2026

AIHC Capital Management Ltd

CIK 0002103725 · UNIT 1506, 15/F, NEXXUS BUILDING, 41 CONNAUGHT ROAD CENTRAL, CENTRAL, 00000 · 85237579883

Reported Value
$120M
Q1 2026
Positions
5
Filings on Record
2
2019–present window
Filed
May 8, 2026
original filing

Summary

Aihc Capital Management Ltd reported $120M in U.S.-listed holdings across 5 positions for Q1 2026.

The portfolio is heavily concentrated: RVMD alone accounts for 67.4% of reported value.

Compared with Q4 2025, the fund opened 1 new position and exited 2.

Portfolio Metrics

Turnover
+27.5%
vs prior filed quarter
Largest Position
+67.4%
Revolution Medicines
New / Exited
1 / 2
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’25: $107MQ4 ’25Q1 ’26: $120MQ1 ’26filingsflow.com

Portfolio Composition

By security type
Common Stock: 95.3%ADR: 4.7%
  • Common Stock · 95.3% · $114M
  • ADR · 4.7% · $6M

Quarter-over-Quarter Changes full breakdown →

vs Q4 2025 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
ORICORIC PHARMACEUTICALS INCNEW+2.46M2.46M+$31M$31M
NBPNOVABRIDGE BIOSCIENCESADDED+1.85M2.26M+$4M$6M
PTGXPROTAGONIST THERAPEUTICS INCSOLD OUT189.8K0$17M$0
AVBPARRIVENT BIOPHARMA INCSOLD OUT644.8K0$13M$0
COGTCOGENT BIOSCIENCES INCTRIMMED48.6K51.4K$2M$2M
RVMDREVOLUTION MEDICINES INCTRIMMED71.4K829.0K+$9M$81M
KRROKORRO BIO INCHELD+030.3K+$100,177$342,600

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2026

5 positions
#IssuerClass% PortfolioValueShares
1RVMDREVOLUTION MEDICINES INChistory →COM67.37%$81M829.0K
2ORICORIC PHARMACEUTICALS INChistory →COM26.04%$31M2.46M
3NBPNOVABRIDGE BIOSCIENCEShistory →SPONSORED ADS4.65%$6M2.26M
4COGTCOGENT BIOSCIENCES INChistory →COM1.65%$2M51.4K
5KRROKORRO BIO INCCOM0.29%$342,60030.3K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$120M5May 8, 202613F-HRchanges · EDGAR ↗
Q4 2025$107M6Feb 5, 202613F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.